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HIGHLIGHTS
• ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl
group from the PF 9601N, a potent and selective MAO B inhibitor. This compound
is the most advanced anti-Alzheimer agent for preclinical studies identified in our
laboratory.
• Derived from ASS234 both multipotent donepezil-indolyl (MTDL-1) and
donepezil-pyridyl hybrids (MTDL-2) were designed and evaluated as inhibitors
of AChE/BuChE and both MAO isoforms. MTDL-2 showed more high affinity toward
the four enzymes than MTDL-1.
• MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety
from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a
N-propargyl core and they were pharmacologically evaluated.
• The presence of the cyano group inMTDL-3, enhanced binding to AChE, BuChE and
MAO A. It showed antioxidant behavior and it was able to strongly complex Cu(II), Zn(II)
and Fe(III).
• MTDL-4 showed higher affinity toward AChE, BuChE.
• MTDL-3 exhibited good brain penetration capacity (ADMET) and less toxicity
than Donepezil. Memory deficits in scopolamine-lesioned animals were restored by
MTDL-3.
• MTDL-3 particularly emerged as a ligand showing remarkable potential benefits for its
use in AD therapy.
Alzheimer’s disease (AD), the most common form of adult onset dementia, is an
age-related neurodegenerative disorder characterized by progressive memory loss,
decline in language skills, and other cognitive impairments. Although its etiology is
not completely known, several factors including deficits of acetylcholine, β-amyloid
deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are
considered to play significant roles in the pathophysiology of this disease. For a
long time, AD patients have been treated with acetylcholinesterase inhibitors such as
donepezil (Aricept®) but with limited therapeutic success. This might be due to the
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complex multifactorial nature of AD, a fact that has prompted the design of new Multi-
Target-Directed Ligands (MTDL) based on the “one molecule, multiple targets” paradigm.
Thus, in this context, different series of novel multifunctional molecules with antioxidant,
anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with
multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase,
butyrylcholinesterase, and monoamine oxidases A and B have been designed and
assessed biologically. This review describes the multiple targets, the design rationale
and an in-house MTDL library, bearing the N-benzylpiperidine motif present in donepezil,
linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline)
with special emphasis on compound ASS234, an N-propargylindole derivative. The
description of the in vitro biological properties of the compounds and discussion of the
corresponding structure-activity-relationships allows us to highlight new issues for the
identification of more efficient MTDL for use in AD therapy.
Keywords: multi-target-directed ligands, donepezil, oxidative stress, anti-β-amyloid aggregation, Alzheimer’s
disease
INTRODUCTION
Alzheimer’s disease (AD) is one of the most common
neurodegenerative diseases accounting for more than 80% of
total dementia cases in elderly people. It is estimated that
currently 47 million victims of AD exist worldwide and that
number is expected to grow up to more than 130 million by
2050 as a result of life expectancy increase over the next decades
(Thies and Bleiler, 2012, 2013). In 2015, the World Alzheimer
Report estimated that the current annual societal and economic
cost of dementia was US $818 billion worldwide and that amount
is expected to rise up to 1 trillion by 2018. This study also reported
that the cost associated with dementia has increased by 35% since
2010.
The clinical manifestations of AD are characterized by
misfunctioning and gradual neuronal death resulting in a
progressive memory deterioration and cognitive decline, related
with the loss of cholinergic dysfunction. The anatomopathology
of AD has been described by progressive loss of synaptic neurons
triggering atrophy in the hippocampus and frontal and tempo-
parietal cortex. Two distinctive hallmarks of AD include the
presence of accumulated amyloid beta (Aβ) plaques around
neurons (Glenner and Murphy, 1989) and hyperphosphorylated
microtubules associated with tau protein in the form of
intracellular neurofibrillary tangles (NFT) (Goedert et al., 2006).
The pathogenesis of this neurodegenerative disorder is not
yet fully understood, but the scientific consensus is quite
firm in describing it as a multifactorial disease caused by
several elements. These include loss of cholinergic transmission,
excessive protein misfolding and Aβ aggregation (Terry et al.,
1964; Grundke-Iqbal et al., 1986), oxidative stress and free radical
formation (Coyle and Puttfarcken, 1993), metal dyshomeostasis
(Huang et al., 2004), excitotoxic, and neuroinflammatory
Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid beta; NFT, neurofibrillary
tangles; AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; MAO,
monoamine oxidase; APP, amyloid precursor protein; ROS, reactive oxygen
species; MTDL, multi-target-directed ligand.
processes (Coyle and Puttfarcken, 1993). Although a large
number of genes has been associated with the AD late-
onset condition, these appear to affect susceptibility or rate of
progression rather than being directly causative (Bertram and
Tanzi, 2008; Chouraki and Seshadri, 2014; Karch and Goate,
2015).
CHOLINERGIC HYPOTHESIS
Cholinergic neurotransmission modulates cognitive function
and cortical plasticity (Arendt and Bigl, 1986) and also plays key
roles in the control of cerebral blood flow (Biesold et al., 1989),
cortical activity (Détári et al., 1999), and the sleep-wake cycle
(Lee et al., 2005). In 1971, Deutsch postulated the involvement of
the cholinergic system in learning and memory (Deutsch, 1971),
which was later corroborated in studies with animal models and
humans (Fibiger, 1991; Schliebs, 2005).
The first physiological evidence for the involvement of
the cholinergic system in AD pathology was a reduction in
pre-synaptic acetylcholine (ACh) and a reduced expression
of choline acetyltransferase (ChAT), the enzyme responsible
for ACh synthesis. In addition, decreases in the binding
parameters of both muscarinic acetylcholine receptors (mAChR)
and nicotinic acetylcholine receptors (nAChR) have been
reported. These findings suggest a direct link between cholinergic
neurotransmission and AD, and constitute the basis for the so-
called “cholinergic hypothesis of AD” (Deutsch, 1971), which the
main therapeutic approach used to date to address the cognitive
loss associated with AD is based on.
Cholinesterases
Cholinesterases (ChE) catalyse the hydrolysis of ACh
into choline and acetic acid, an essential process in
the cholinergic neurotransmission. There are two types
of ChEs: acetylcholinesterase (AChE, EC 3.1.1.7) and
butyrylcholinesterase (BuChE, EC 3.1.1.8). Both enzymes
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are type α/β hydrolases folded with an α-helix bound with
β-sheet containing a catalytic domain (Ollis et al., 1992).
Acetylcholinesterase
AChE is expressed in cholinergic neurons and neuromuscular
junctions where its primary function is the rapid breakdown
of the neurotransmitter ACh released during cholinergic
neurotransmission. Although AChE and BuChE are structurally
similar, resembling each other by more than 50%, both their
significance and location are substantially different.
The structure of AChE has been widely studied since the
1990s. The active site of the enzyme lies on a bottom of a
long and narrow cavity of 20 Å deep and contains a catalytic
triad with amino acid residues Ser200, His440 and Glu327
that catalyses the hydrolysis of the ester bond. The active site
also includes an anionic site or α-anionic site that interacts
with the quaternary ammonium atom of ACh, ensuring its
correct orientation. A peripheral anionic site (PAS) or β-anionic
site, located on the enzyme surface around the cavity entrance
(Figure 1) has been described to play an important role in AD.
This site was first recognized in the 1960s as a target for AChE
activity modulators (see Sussman et al., 1991) such as toxins
and promising drugs. Furthermore, interaction of the Aβ peptide
with the PAS contributes to the formation of amyloid plaques
by accelerating the aggregation process. Propidium iodide is an
example of an inhibitor binding to this site (Inestrosa et al., 1996).
One of the most consistent changes associated with AD
has been the degeneration of neurons from the cholinergic
nuclei in the basal forebrain region and their terminals in the
hippocampus (Struble et al., 1982). The neuronal atrophy has
been associated with a loss of cholinergic markers, occurring
FIGURE 1 | Structure of AChE displaying the active site at the bottom of
a narrow gorge, lined with hydrophobic amino-acid side chains within
the catalytic triad, the choline binding site, and the peripheral binding
site (Reproduced, with permission from Soreq and Seidman, 2001).
specifically in the nucleus basalis of Meynert (Vogels et al., 1990).
The cholinergic system function, responsible for the storage and
retrieval of items in memory, is therefore highly impaired in AD
pathology, which has been corroborated by some neuroimaging
data (Jack et al., 2010).
Butyrylcholinesterase
BuChE is expressed in the hippocampus and temporal neocortex
but at lower levels than AChE, and associated with glial cells
(Mesulam et al., 2002), suggesting that these enzymes may have
complementary functions. In AD brain, neuritic plaques, and
NFTs contain large amounts of AChE and BuChE, the latter
being present in the neuroglia (Wright et al., 1993), Moreover,
these enzymes have been reported to play a role in the processing
of APP (Wright et al., 1993), although it is unclear whether
their inhibition could influence the pathogenic course of AD.
While AChE is expressed in nerve and blood cells, hydrolysing
ACh, the biological significance of BuChE still remains poorly
understood, although it has been reported to partially modulate
or compensate for the diminished AChE activity in deficient
animals (Xie et al., 2000).
Likewise AChE, glial BuChE hydrolyses ACh into choline and
acetate (Daikhin and Yudkoff, 2000; Mesulam et al., 2002) but
with a different kinetic behavior. While AChE predominates in
neurons and exhibits high affinity for ACh, with low KM values,
BuChE is mainly present in endothelia, glia and neuronal cells
with low affinity (high KM value) for ACh (Soreq and Seidman,
2001).
In addition to its role in the hydrolysis of ACh, non-enzymatic
functions have also been attributed to BuChE. Whereas, AChE
may accelerate amyloid deposition in the brain of AD patients,
as previously mentioned, BuChE can associate with Aβ protein
possibly delaying the onset and rate of neurotoxic Aβ fibril
formation as observed in vitro (Diamant et al., 2006).
Activity of BuChE has been found either unaltered or
increased in certain AD brain regions (Perry et al., 1978; Ciro
et al., 2012). The increase has been associated with amyloid
plaques and NFTs (Geula and Mesulam, 1989; Guillozet et al.,
1997). In addition to changes in activity, changes in AChE and
BuChE protein expression also occur during the progression of
AD. An increase in the levels of glial-derived BuChE and decrease
in synaptic AChE have been observed, triggering a dramatic
increase in the BuChE: AChE ratio in cortical regions from 0.6, in
healthy conditions, to 11 in AD pathology (Giacobini, 2003). The
observed changes in BuChE activity and expression throughout
the course of AD, and its relationship with cognitive function,
emphasize the potential value of BuChE and AChE inhibition as
therapeutic targets in AD condition.
AMYLOID HYPOTHESIS
The amyloid cascade hypothesis postulates that
neurodegeneration in AD is caused by abnormal accumulation
of Aβ plaques in various areas of the brain (Hardy and Higgins,
1992; Evin and Weidemann, 2002). This accumulation acts as a
pathological trigger for a cascade that includes neuritic injury,
formation of NFTs via tau protein to neuronal dysfunction
and cell death (Hardy and Higgins, 1992; Selkoe, 1994).
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Genetic, biochemical, and pathological evidences support this
hypothesis as the primary cause of AD (Kayed et al., 2003).
The Aβ senile plaques are composed by Aβ peptides, which
consist of 39–43 amino acid residues proteolytically derived
from the sequential enzymatic action of β- and γ-secretases
on transmembrane APP (Coulson et al., 2000). The length of
Aβ peptides varies at the C-terminal according to the cleavage
pattern of APP, with Aβ1−40 being the most prevalent form,
followed by the hydrophobic form Aβ1−42 that aggregates
faster (Perl, 2010). Within plaques, Aβ peptides and β-sheet
conformation assemble and polymerise into structurally distinct
forms such as fibrils, protofibers, and polymorphic oligomers
(Selkoe, 1994).
The kinetics of the aggregation process of Aβ peptide follows
a sigmoidal curve owing to the presence of β-sheets in its
structure (LeVine, 1993), and it can be monitored in vitro by
the use of dying molecules. The aggregating process comprises
two main phases: lag phase and elongation phase. Over the lag or
nucleation phase, soluble monomers or dimers with random-coil
structures form a nucleus that proceeds rapidly to the formation
of fibrils. At the end of this phase, low-weight soluble oligomeric
species are formed, which are spherical, globular, and described
as micelles or amorphous aggregates. The molecular mass of
these species varies between 25 and 50 KDa (Lambert et al.,
1998). Throughout the elongation phase, the oligomeric species
link together to form high-molecular weight oligomers of up to
1000 KDa approximately, (Huang et al., 2000). These prefibrillar
species transform into protofilaments or protofibrils, which are
short, flexible, and fibrillar. The protofibrils are the precursors of
full-length fibrils that are formed by simple lateral association and
structural organization. Mature fibrils are straight, unbranched,
twisted and can reach up to 10µm in length (Dobson and Batich,
2004).
The Aβ aggregation process is highly susceptible to many
factors, including pH, ionic strength of the solvent, purification
process or temperature. These are responsible for complications
in reproducibility when experimentally assayed in vitro. Distinct
oligomerisation and assembly processes between Aβ1−40 and
Aβ1−42 have been described (Bitan et al., 2003). While Aβ1−42
exhibits higher neurotoxicity and is able to form hexamers,
heptamers, or octamers, Aβ1−40 reaches equilibrium from
monomers to tetramers. These variances are related to differences
in the Ile-41-Ala-42 dipeptide at the C-terminus of Aβ. Until
recently, it was assumed that fibrillary Aβ deposits were the
responsible agents for the neuronal injury and neurodegenerative
process of AD (Hardy andHiggins, 1992; Selkoe, 1994). However,
later findings showed that soluble oligomeric species were
able to disrupt synaptic function (Lambert et al., 1998) and
recent data support the belief that soluble dimeric species
are highly toxic (Jin et al., 2011). The mechanism by which
Aβ induces cell damage has been reported to be caused by
reactive oxygen species (ROS) production (Schubert et al.,
1995), altered signaling pathways (Mattson, 1997), mitochondrial
dysfunction (Shoffner, 1997), and interaction with biometals
(Jin et al., 2011).
Both Aβ deposition and plaque formation also lead to local
microglia activation, cytokine release, reactive astrocytosis, and
multi-protein inflammatory responses (Heppner et al., 2015;
Figure 2). The multifaceted biochemical and structural changes
in surrounding axons, dendrites, and neuronal cell bodies also
FIGURE 2 | Role of APP cleavage processing in AD and microglial activation (Reproduced, with permission from Heppner et al., 2015).
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induce synapse loss as well as a remarkable cerebral atrophy in
AD (Braak and Braak, 1994).
Nonetheless, to date no correlation between Aβ accumulation
with extent of neuronal loss and cognitive dysfunction has
been reported. In addition, direct Aβ-peptide neurotoxicity has
been difficult to be identified in animal models, suggesting
the existence of key intermediates between amyloidosis and
neurodegeneration (Nelson et al., 2012; Serrano-Pozo et al.,
2013). In addition to these studies, genetic research has suggested
that neurodegenerative processes occurring in AD are the
consequence of an imbalance between Aβ peptide production
and clearance. Since the postulation of the amyloid hypothesis
of AD, extensive but, so far unsuccessful, efforts have been
undertaken in clinical research in order to develop novel
therapeutics, this hypothesis has continued to gain support over
the last two decades, particularly from genetic studies.
OXIDATIVE STRESS
Within any functional aerobic cell, the process involved
in respiration inevitably generates ROS (Petersen et al.,
2007). In particular, redox reactions are necessary for
the generation of ATP and free radical intermediates are
produced via the establishment of a proton gradient in
oxidative phosphorylation. Multiple damaging mechanisms
coexist in AD pathology, affecting each other at multiple
levels (Von Bernhardi and Eugenín, 2012). In this respect,
oxidative stress, which could be secondary to several other
pathophysiological events, appears to be central in the
progression of AD pathogenesis. Experimental evidence
indicates that disturbances of the tissue redox state are
important factors in early-stage AD, including the activation
of multiple cell signaling pathways that contribute to the initial
progression of the neurodegenerative process (Feng and Wang,
2012).
Evidence of ROS and reactive nitrogen species (RNS)-
mediated injury has been reported in AD (Praticò, 2008).
Increased levels of oxidative damage to biomolecules including
proteins, lipids, carbohydrates, and nucleic acids have been
detected in a number of studies (Moreira et al., 2008; Fukuda
et al., 2009; Sultana et al., 2011). In addition, levels of
antioxidant enzymes were found to be altered in specific AD
brain regions (Sultana et al., 2011). Consequently, the “oxidative
stress hypothesis of AD” emerged as a key factor in both
the onset and progression of the disease. Oxidative stress is
a widespread cellular process that currently lacks a specific
treatment target such as a receptor or a single major metabolic
pathway (Galasko et al., 2012). The wide variety of sources and
sites of oxidative stress production paralleled by an even higher
heterogeneity in the antioxidant responses. Specifically, the
activity of cytochrome oxidase and pyruvate and α-ketoglutarate
dehydrogenase complexes (key enzymes for the ATP supply) have
been reported to be decreased as a result of oxidative damage
(Aliev et al., 2011). In AD, there are established connexions
between oxidative stress and other key AD events that amplify
its complexity (Figure 3).
The presence of oxidation markers in the early stages of
AD indicates that oxidative stress precedes the appearance
of some other hallmarks (Rosini et al., 2014). Moreover,
the accumulation of oxidative active modified products,
such as 8-hydroxyguanosine (8-OHG) and nitrotyrosine in
the cytoplasm of cerebral neurons from Down’s syndrome
patients has been reported to precede amyloid deposition
(Odetti et al., 1998; Nunomura et al., 2000). This finding was
also demonstrated in an APP transgenic mice model of AD
(Smith et al., 1998). In post-mortem brains of myocardial
infarction (MCI) patients, CSF, plasma, and urine increased
levels of lipid peroxidation, nuclear acid oxidation, and
diminished levels of antioxidant enzymes were found
(Keller et al., 2005; Butterfield et al., 2006). Furthermore,
heme oxygenase-1 (HO-1) levels were also reported to be
increased in both AD and MCI post-mortem brain tissues
(Schipper et al., 2006). Such findings might indicate increased
oxidative stress as a general response to tissue damage in
the brain, which may therefore contribute to its further
progression.
Although Aβ and its aggregated senile plaques are
undoubtedly involved in the neurodegenerative process of
AD, the chronology of their presence has been now deemed
secondary by many studies (Castellani et al., 2006; Zhu et al.,
2007). Evidence suggests that secretion and deposition of
Aβ within the neurons are compensatory measures taken by
cells in effort to protect themselves against damage triggered
by oxidative stress (Hayashi et al., 2007; Nakamura et al.,
2007). Mitochondrial abnormalities, initially caused by gradual
oxidative disturbances are major contributors of ROS to the cell
(Bonda et al., 2010). Oxidative perturbances in mitochondrial
operations result in impaired metabolic capacity (Wang et al.,
2009) that would prevent the effective transfer of electrons
along the respiratory chain during oxidative phosphorylation
and the further generation of excessive ROS. This abnormality
creates a vicious positive-feedback cycle where ROS produce
oxidative stress that eventually yields more ROS along with
other cellular detriments. ROS gradually accumulate in the cell
and once a threshold is reached, it is no longer able to control
the debilitating cycle propagation and a compensatory “steady
state” is unavoidably initiated in order to regain control of its
environment (Zhu et al., 2007). This hyper-defensive state,
intended to prolong cell life, increases vulnerability to additional
insults such as Aβ peptides. The cell therefore becomes
subject to oxidative damage produced by oligomerisation
and aggregation (Wang et al., 2009), that in turn, leads to
neuroinflammation, mitochondrial damage, and further ROS
generation.
In addition, cellular oxidative damage has also been linked
to tau hyperphosphorylation and formation of NFTs (Lee et al.,
2004). As a consequence of this aberrant cycle, cells succumb
to neurodegeneration exhibiting the distinctive cognitive decline
and dementia descriptive of AD (Zhu et al., 2007). Altogether,
the primary role of oxidative stress in both AD onset
and progression open the possibility of developing specific
disease-modifying antioxidant approaches to confronting the
disease.
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FIGURE 3 | Prevailing connections between oxidative stress and other key players in AD (Reproduced, with permission from Mattson, 2004).
BIOMETAL DYSHOMEOSTASIS
Numerous studies in AD and other neurodegenerative disorders
have described an increase in the levels of oxidative stress
reflected by a deregulated content of metals iron, copper, and
zinc in the brain of patients. Recent findings have strongly
pointed to brain oxidative stress as one of the earliest changes
in AD pathogenesis that might play a central role in the disease
progression (Guglielmotto et al., 2010; Lee et al., 2010). Redox-
activemetals, especially Fe2+ and Cu2+ are capable of stimulating
free radical formation via the Fenton reaction, thereby increasing
protein and DNA oxidation and enhancing lipid peroxidation
(Khalil et al., 2011).
Metal ions have also been reported to mediate Aβ toxicity
in AD (Duce et al., 2010). The Aβ peptide itself has been
shown to be a strong redox-active catalyst able to produce
hydrogen peroxide and OH− in presence of copper or iron,
which, in turn, are enriched in the amyloid cores of senile plaques
(Huang et al., 1999, 2004). Metal ions can also interact with
Aβ peptide enhancing its self-aggregation and oligomerisation
at low physiological concentrations or under mildly acidic
conditions (Huang et al., 1999). Moreover, metals can promote
tau hyperphosphorylation and subsequent formation of NFTs by
inducing aggregation upon tau interaction with Aβ (Yamamoto
et al., 2002).
The presence of an iron-responsive element (IRE) in the 5′
untranslated regions (UTR) of AβPP mRNA was revealed as
another link between iron metabolism and AD (Rogers et al.,
2002; Silvestri and Camaschella, 2008). Iron closely upregulates
intracellular levels of APP holo-protein by a mechanism that is
similar to the translational control of ferritin L- and H- mRNAs
through an IRE in their 5′ UTR (Rogers et al., 2002; Silvestri and
Camaschella, 2008).
The Role of Copper in AD
Copper is an essential trace element for all living animals.
Copper levels are controlled by homeostatic mechanisms to
prevent an excess, or a deficiency, that may trigger a unique
set of adverse health effects. Copper can undergo redox cycling
between Cu1+ and Cu2+ and the activities of some copper-
containing enzymes, including superoxide dismutase (SOD),
cytochrome-c oxidase, ceruloplasmin, and tyrosinase, have
important biological functions. However, copper is also involved
in the formation of free radicals by the Fenton reaction, in which
free copper catalyses the formation of toxic hydroxyl radicals
from physiologically available hydrogen peroxide (Barnham
et al., 2004). Two classic disorders related to copper metabolism
are Menkes and Wilson diseases, in which neurodegeneration
is a common complication (Kodama et al., 1999; Merle et al.,
2007).
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In AD pathology, copper is mislocalized in brains, where
decreased levels of this metal have been reported in affected
regions (Deibel et al., 1996; Magaki et al., 2007) with enrichment
in amyloid plaques and tangles (Lovell et al., 1998). Copper is
released into the glutamatergic synaptic cleft facilitated by the
copper-transporting P-type ATPase ATP7A at concentrations of
∼15 µM (Hartter and Barnea, 1988; Hopt et al., 2003). There,
it causes S-nitrosylation of NMDA receptors, inhibiting their
activation (Schlief et al., 2005, 2006).
Aβ toxicity has been linked to the presence of redox metals,
especially the binding to copper as well as the non-redox zinc
ions (Hou and Zagorski, 2006; Tougu et al., 2008), although the
precise mechanisms involved are still under investigation (Syme
et al., 2004; Ma et al., 2006; Minicozzi et al., 2008; Alies et al.,
2011). The copper binding site to Aβ1−42 has high affinity (Kd
= 7.03 10−18 M; logKapp = 17.2), as measured by competitive
metal-capture analysis, whereas that of Aβ1−40 is 10.3 (Atwood
et al., 2000). The binding to copper has also been shown tomodify
and accelerate Aβ aggregation.
Copper also promotes dityrosine cross-linking of Aβ, which
further accelerates Aβ aggregation (Atwood et al., 2000; Ali et al.,
2005). The copper-induced Aβ oligomer contains a membrane-
penetrating structure with histidine bridging (Curtain et al.,
2001; Smith et al., 2006). This fact underlines the importance of
histidine in the copper-Aβ interaction, which results in oligomers
rather than the fibrils that are formed in the presence of zinc
(Jiao and Yang, 2007). The copper-Aβ complex has been reported
to exhibit cytotoxic properties (You et al., 2012) as this binding
increases Aβ-induced cell death in cell culture (Wu et al., 2008;
Perrone et al., 2010). Some hypotheses for this finding include the
inhibition of cytochrome c (Crouch et al., 2005) and the increase
of oxidative stress, triggered by the generation of hydrogen
peroxide by Aβ and copper via a catalytic cycle (Huang et al.,
1999). APP also interacts with copper by binding it between
residues 142 and 166 (White et al., 1999; Barnham et al., 2003;
Cappai et al., 2004) and catalytically oxidizing Cu1+ to Cu2+
(Multhaup et al., 1996). Furthermore, copper promotes APP
internalization, whereas copper deficiency promotes Aβ secretion
but not APP cleavage (Acevedo et al., 2011). Therefore, APP
may not directly influence copper homeostasis, but inappropriate
interaction with copper may be neurotoxic.
Tau phosphorylation and aggregation may also be induced
by copper. Certain fragments in the four-repeat microtubule-
binding domain of tau were shown to aggregate in the presence
of copper in vitro (Ma et al., 2006; Zhou et al., 2007). Copper
binding to tau induces hydrogen peroxide production in vitro
(Su et al., 2007) and NFTs have also been shown to bind to
copper in a redox-dependent manner as a source of ROS within
the neuron (Sayre et al., 2000). In addition, copper exposure has
been reported to induce tau hyperphosphorylation promoting
tau pathology in a mouse model of AD (Kitazawa et al., 2009).
The Role of Zinc in AD
The brain is the main pool of zinc within the body (Frederickson,
1989). Zinc is an essential component for many enzymes and
transcription factors. In healthy conditions, most of the zinc
content is located in membrane-bound metalloproteins (MP I,
II, and III), loosely bound to zinc within the cytoplasm, and
vesicular zinc, enriched in synapses. It has several functional
roles in signal transmission. Synaptic transmission releases high
concentrations of zinc into the synaptic cleft (Frederickson, 1989;
Vogt et al., 2000; Qian and Noebels, 2005), where it acts as an
antagonist of GABA (Molnar and Nadler, 2001; Ruiz et al., 2004)
and NMDA receptors (Paoletti et al., 1997; Traynelis et al., 1998;
Vogt et al., 2000) and activates the G-protein-coupled receptor
GPR39 (Besser et al., 2009).
Inconsistent reports of zinc levels in AD have been published.
Early surveys of brain tissue found no difference in zinc levels
between AD and controls. Yet, later studies showed a decrease
in zinc levels in neo-cortex (Danscher et al., 1997), superior
frontal and parietal gyri, medial temporal gyrus and thalamus and
hippocampus (Corrigan et al., 1993; Panayi et al., 2002). However,
in other reports elevated zinc levels in AD-affected amygdala,
hippocampus and cerebellum, (Deibel et al., 1996; Danscher et al.,
1997), olfactory areas (Samudralwar et al., 1995), and superior
temporal gyrus (Religa et al., 2006) were described.
The cause of this apparent zinc dysregulation remains
unknown, yet it may be involved in alterations of proteins
such as metallothionein III, which is found in neurons and
reduced in AD brains (Uchida et al., 1991; Yu et al., 2001). In
contrast, metallothionein I/II was found increased in astrocytes
of post-mortem and preclinical AD brains (Adlard et al., 1998).
In AD pathogenesis, enriched zinc levels have been found in
amyloid plaques (Bush et al., 1994c). Studies using microparticle-
induced X-ray emission tomography demonstrated a three-fold
in zinc concentrations-surrounding neuropils in the amigdala
(Lovell et al., 1998). These findings were later corroborated by
histochemistry (Suh et al., 2000), autometallographic tracing
(Stoltenberg et al., 2005) and synchrotron-based infrared and
X-ray imaging (Miller et al., 2006).
Aβ binds to zinc at residues 6–28 (Bush et al., 1993, 1994a,b,c),
with up to three zinc ions bound to histidines 6, 13, and 14
(Damante et al., 2009), inducing the aggregation of Aβ into
soluble precipitates (Bush et al., 1994c). Therefore, zinc, like
copper, accelerates Aβ-induced toxicity and zinc sequestration
into amyloid deposits (Bush et al., 1994c) (Faller et al., 2013),
inducing loss of functional zinc in the synapses. This loss may
contribute to cognitive decline in AD due to ZnT-3 depletion
(Adlard et al., 2010).
Zinc may also interfere with APP processing and function
as these processes are coordinated by secretases under the zinc
regulation. This metal increases the synthesis of PS-1 (Park
et al., 2001); however, the γ-secretase activity is inhibited by
Zn2+ (Hoke et al., 2007). Zinc binds directly to Aβ, hiding
its proteolytic cleavage site (Bush et al., 1994b) and therefore
inhibiting its degradation by matrix metalloproteases (Crouch
et al., 2009). Secreted Aβ is normally degraded by proteases such
as neprilysin within a short period of time. However, zinc and
other metals enhance the oligomerisation and accumulation of
the amyloid protein.
After being incorporated into the membrane, the
conformation of Aβ changes and it aggregates on the
membranes. These aggregates are able to form channels,
which unlike endogenous Ca2+ channels, are not regulated by
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standard channel blockers. Thus, a continuous flow of Ca2+ is
initiated and disruption of calcium homeostasis triggers several
apoptotic pathways, including free radical formation and tau
phosphorylation leading to cell death. Conversely, zinc secreted
into synaptic clefts, inhibits Aβ-induced Ca2+ entry, and thus
confers a protective function in AD (Kawahara et al., 2014).
In agreement with these findings, in vivo studies revealed that
high intake of dietary zinc triggered elevated expression of APP
and enhanced amyloidogenic APP cleavage and Aβ deposition
in APP/PS1 transgenic mice (Borchardt et al., 2000; Cuajuangco
and Faget, 2003; Wang et al., 2010). Finally, zinc may also be
involved in tau pathology as it is enriched in tangle-containing
neurons (Suh et al., 2000). Zinc moderates translation of tau and
modulates its phosphorylation by affecting the activities of GSK-
3β, protein kinase B, ERK1/2, and c-Jun N-terminal kinase (An
et al., 2005; Pei et al., 2006; Lei et al., 2011). Zinc can also bind to
tau monomers, altering their conformation (Boom et al., 2009)
and inducing both aggregation and fibrillation of this protein
(Mo et al., 2009).
The Role of Iron in AD
Iron is a fundamental element in biology for oxygen transport
and energy metabolism. It is a transition element that exists
in oxidative states from −2 to +8, although in biological
systems only ferrous (Fe2+) and ferric (Fe3+) states normally
exist. The cycling between ferric to ferrous states is used in
biology for various redox reactions essential to life. However,
deleterious reactions with oxygen, such as Fenton reaction, which
is catalyzed by the free ferrous iron and may involve bound
Fe(IV) (Freinbichler et al., 2009) are a source of oxidative stress
(Zigler et al., 2015).
In the brain, iron is involved in development (Beard,
2003), metabolic and neurotransmitter systems (Agarwal, 2001).
It is therefore regulated by multiple proteins, reflecting its
involvement in different cellular functions. In AD brains, iron
is enriched in both NFTs (Smith et al., 1998) and senile plaques
(Goodman, 1953) with an estimated concentration of three-fold
higher that of the normal neuropil levels (Lovell et al., 1998).
Iron accumulation occurs in the cortex but not in the cerebellum
(Andrasi et al., 1995; Duce et al., 2010). The iron storage protein
ferritin binds to most iron within the brain and its levels increase
with age and in AD (Bartzokis and Tishler, 2000). Transferrin
(Tf) is an extracellular iron-transporting protein expressed in the
brain that exchanges iron between cells. The complex Fe-Tf is
endocytosed (Eckenroth et al., 2011) and iron is reduced to its
ferrous state by an unknown ferrirreductase.
Recently, AD-associated APP was identified as a neuronal
ferroxidase (Duce et al., 2010). APP-knockout mice exhibit iron
accumulation in the brain and peripheral tissues and loss of APP
ferroxidase activity in AD brains is coincident with iron retention
in the tissues (Duce et al., 2010). Recent studies reported that
iron-export capability of APP requires tau protein (Lei et al.,
2012), which is involved in axonal transport (Lei et al., 2010) and
binds to APP (Islam and Levy, 1997). Moreover, the loss of tau in
mice is reported to cause age-related iron accumulation (Lei et al.,
2012). The iron-regulatory system is disturbed in AD brains and
ferritin has been reported to be elevated and co-localized with
senile plaques expressed in astrocytes (Connor et al., 1992) and
increased in frontal cortex of AD brains (Loeﬄer et al., 1995).
However, the amount of APP was not significantly reduced in
cortex (Duce et al., 2010) but both ferroxidase activity and soluble
tau protein levels were observed to be decreased (Shin et al., 1992;
Khatoon et al., 1994; Zhukareva et al., 2001; Van Eersel et al.,
2009; Duce et al., 2010). Genetic factors have also been linked to
higher susceptibility to iron burden in AD (Blázquez et al., 2007;
Bertram and Tanzi, 2008; Percy et al., 2008).
Iron burden enriches around the senile plaque region
(Meadowcroft et al., 2009) and promotes Aβ aggregation in vitro
(Mantyh et al., 1993). Furthermore, iron-aggregated Aβ toxicity
in cell culture (Schubert and Chevion, 1995) is mediated by ROS
production (Rottkamp et al., 2001) or by the activation of Bcl-
2/Bax-related apoptosis pathway (Kuperstein and Yavin, 2003).
As mentioned above, iron also binds to tau protein, but only
Fe3+ has reported to induce aggregation of hyperphosphorylated
tau protein, which can be reversed by reducing Fe3+ to Fe2+
(Yamamoto et al., 2002) or by the use of iron-chelators (Amit
et al., 2008). In AD brain, NFTs bind iron, which acts as
a source of ROS within the neurons (Sayre et al., 2000).
A decrease of tau phosphorylation in hippocampal neurons
treated with Fe3+ (Egaña et al., 2003), corresponding with a
decrease in CDK5 activity. Conversely, treatment with Fe2+
also resulted in hyperphosphorylation (Lovell et al., 2004)
without inducing aggregation, possibly resulting from upstream
activation of the ERK1/2, MAPK pathway (Muñoz et al.,
2006; Huang et al., 2007). Recently, oxygen tension-dependent
transcriptional factor, hypoxia inducible factor-1α (HIF-1α) has
emerged as a potential target in neurodegenerative diseases. This
protein regulates intracellular iron by binding to HIF-responsive
elements (HREs) that are located within the genes of iron-related
proteins such as Tf receptor and heme oxygenase-1 (Petousi and
Robbins, 2014).
Recent research and clinical trials have confirmed that HIF-
1α activation may be a potent strategy for postponing the
pathogenesis and ameliorating the outcomes of AD. In this
context, the use of iron chelators such as M30 has been reported
to increase the levels of this protein by inducing the expression
of its target genes VEGF and EPO. In addition, overexpression
of HIF-1α has been shown to protect cultured cortical neurons
from Aβ-induced neurotoxicity, through activating glycolytic
and hexose monophosphate shunt-related enzymes. Therefore,
an additional use of iron-chelators to overexpress HIF-1α
may contribute to preventing neuron death and ameliorating
the symptomatology of AD by inducing the expression of
neuroprotection-related genes (Benkler et al., 2010).
Thus, in the context of AD pathology, the involvement of
both oxidative stress and metal ions in AD (Ayton et al.,
2013), indicates the use of antioxidant-chelators as potential
beneficial agents in the prevention and treatment of the disease,
by scavenging free radicals and, more importantly, by blocking
their production, as well as restoring normal metal balance.
Although abnormal accumulation of metals has been reported
in AD for many years, it has been only recently considered
as a key early factor in AD, closely related to increased levels
of both oxidative stress and amyloid beta-protein toxicity in
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Barone (2016). The development of metal-chelators has emerged,
concurrently, as a novel pharmacological approach against this
neurological disorder. In this regard Youdim and co-workers
have reported a novel multifunctional molecule, M30, which
combines iron-chelation with and monoamine oxidase (MAO)
inhibitory properties as a possible drug for the treatment of AD
(Zheng et al., 2005; Avramovich-Tirosh et al., 2007).
NEUROINFLAMMATION
Inflammation is a defensive mechanism of the body against
multiple threats such as infections and injury. It is a complex
event that involves both soluble factors and specialized cells
(Brown et al., 2007). Similar inflammatory processes occur
in the brain and peripheral tissues. In the brain, glial cells,
including astrocytes and microglia, undergo activation under
pro-inflammatory conditions by the increase in the production
of inflammatory cytokines in the CNS, which become deleterious
and leads to progressive tissue damage in degenerative diseases
(Morales et al., 2014). Infiltration by peripheral macrophagesmay
also occur (Rogers et al., 1996).
In chronic disorders such as AD pathology, inflammation
plays a critical role. It has been reported that insoluble fibrillar
Aβ surrounding microglia, reactive astrocytes and dystrophic
neurites contributes to the process of neuronal degeneration by
initiating a series of cellular events which are able to elicit an
immune response. Moreover, Aβ deposition in parenchyma and
blood vessels has been described to trigger microglial migration
and mediation of acute and chronic inflammatory response
against the aggregates, thus inducing the production of nitric
oxide (NO), ROS, pro-inflammatory cytokines such as tumor
necrotic factor α (TNFα) or inteleukins-1β and -6 (IL-1β, IL-
6) and prostaglandin E2 (PGE2), which eventually may promote
neuronal death (Kitazawa et al., 2009).
MAO AS A TARGET
One of the major observations in late AD is the loss of neuronal
cells and brain shrinkage. Specific loss of dopaminergic cells has
led to the use of deprenyl or selegiline as adjunctive therapy in
PD to prevent removal of dopamine by metabolism (Birkmayer
et al., 1977). The same principle applies in AD, where the decrease
in all neurotransmitters is due mainly to a loss of neuronal
connections.
Monoamine oxidases (MAO, EC 1.4.3.4) are flavin adenine
dinucleotide (FAD)-containing enzymes that catalyse the
oxidative deamination of primary, secondary, or tertiary amines,
producing the corresponding aldehyde, hydrogen peroxide and
ammonia. There are two isoforms of MAO present in mammals:
MAO A and MAO B, which share ∼70% sequence identity and
are encoded by separate genes located on the X chromosome.
The C-terminal regions of MAOs are transmembrane α-helices
that anchor the enzymes to the mitochondrial outer membrane
leaving the rest of the protein exposed to the cytoplasm. The
entry of a substrate or inhibitor into the active site of MAOs is
predicted to occur near the intersection of the enzyme with the
surface of the membrane (De Colibus et al., 2005; Edmondson
et al., 2007).
In selective MAO-knockout mice, the two MAO isoforms
resulted in significantly different effects on both metabolism
and behavior. Whereas, the lack of MAO A triggered aggressive
phenotypes as a result of elevated levels of 5-HT and NA
and lesser of DA (Chester et al., 2015), only the levels of 2-
phenylethylamine were increased in MAO B-knockout mice,
which exhibited traits such as sensation seeking, impulsiveness
and extraversion. MAO A and MAO B were originally
distinguished by their sensitivity to nanomolar concentrations of
the acetylenic inhibitors clorgyline and l-deprenyl, respectively,
as well as by their substrate specificities. The content of MAO
varies over lifetime as MAO A appears before MAO B, the brain
level of which increases dramatically after birth (Tsang et al.,
1986; Strolin-Benedetti et al., 1992; Nicotra et al., 2004). MAO
B levels continue to increase throughout the lifetime and in AD
progression. In rat peripheral nervous system, MAO is localized
in the endothelial cells of the endoneurial vessels, Schwann cells
and unmyelinated axons of some neurons (Matsubayashi et al.,
1986).
In human brain, MAO activity differs among regions.
While the highest levels are found in basal ganglia and
hippocampus, the lowest are observed in the cerebellum and
neocortex (O’Carroll et al., 1983). The anatomical distribution
of MAO isoforms in human brains were confirmed by
positron-emission topography (PET) using intravenous 11C-
labeled irreversible inhibitors (Fowler et al., 1987; Saura
et al., 1992). Immunohistochemical studies have revealed that
serotonergic neurons and astrocytes are rich in MAO B whereas
catecholaminergic neurons mainly contain MAO A (Westlund
et al., 1988). Caudate dopaminergic nerve endings contain only
MAO A and small amounts of this isoform are also found in
the serotonergic nerve terminals (O’Carroll et al., 1987). Some
differences in the dopamine metabolism have been observed
between species. For instance, only MAO A isoform is involved
in rat brain, whereasMAOB is primary responsible for dopamine
metabolism in human brain (Fornai et al., 1999).
Inhibitors of MAO, reversible and irreversible, equipotent
on both isoforms or highly selective, have been used for more
than 60 years for the treatment of depression (Mendelewicz
and Youdim, 1983; Youdim et al., 2006). The most successful
approach has been the use of selective irreversible inhibitors as
exemplified by deprenyl, now used in PD therapy. The chemical
moiety of this compound includes the propargyl group, which
is readily incorporated into different scaffolds to cause MAO
inhibition in compounds that are designed for other targets. This
finding has been identified as one of the mechanisms of various
MTDL to delay the progression of neurodegeneration as it will be
discussed below.
FDA-APPROVED DRUGS FOR AD
At present, only five drugs have been approved by the
U.S. Food and Drug Administration (FDA, USA) for use in
AD. These compounds are mainly based on the “cholinergic
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hypothesis” and aimed at re-establishing functional cholinergic
neurotransmission. Four of these: tacrine (1), rivastigmine (2),
donepezil (3), and galantamine (4) are cholinesterase inhibitors,
whereas memantine (5) is a NMDA receptor antagonist
(Figure 4).
Tacrine
Tacrine or tetrahydroaminoacridine (THA), marketed as
Cognex R©, was the first drug to be approved for use in AD by
the FDA in 1993. It is a competitive AChE inhibitor with high
lipid solubility (Nielsen et al., 1989) also able to interact with
muscarinic receptors (Adem, 1993) and MAO A and B (Adem
et al., 1989). Although it had some relatively small benefits on
cognition, tacrine was withdrawn from the market in 2013 due to
the high incidence of side effects, mostly related to hepatotoxicity
(Qizilbash et al., 1998).
Rivastigmine
Rivastigmine, marketed under the trade name of Exelon R© since
1998, is a non-selective pseudoreversible ChE inhibitor reported
to produce enhanced benefits over AChE inhibition alone
(Touchon et al., 2006; Bullock and Lane, 2007). A recent study
using a transdermal patch reported a reduction in the prevalence
of side effects as well as positive results after administering
rivastigmine to mild-to-moderate AD patients. These studies
reported better outcomes, in comparison with placebo group, for
rate of cognitive function decline and daily living activities (Birks
et al., 2015).
Galantamine
Galantamine (Razadyne R©) is a well-studied drug approved in
2001 for the treatment of AD, possessing a dual mechanism
of action to attenuate the symptoms of cognitive decline in
AD. It is a reversible selective competitive AChE inhibitor
(Greenblatt et al., 1999) that is able to simultaneously modulate
nAChERs (Dajas-Bailador et al., 2003). The main mechanism
of action of this molecule is the ability to increase the
content of ACh, enhancing cholinergic neurotransmission and
therefore improving cognition in AD patients by delay of
ACh catabolism at synapse. Moreover, galantamine has also
demonstrated to directly interact with the nAChER as low-
affinity agonist, allosterically binding to a distinct binding
site from where nicotinic agonists, such as ACh, choline,
or carbachol, bind (Akk and Steinbach, 2005). Moriguchi
et al. (2003) showed that galantamine also potentiates the
activity of NMDARs, so that the dual mechanism of action
on both cholinergic and glutamatergic systems in AD patients
may elucidate the improvement in cognition, memory, and
learning that have been found in clinical trials with this drug
(Wilkinson and Murray, 2001).
Memantine
Memantine, marketed as Namenda R© or Ebixa R©, is a
glutamatergic agent and the first and only NMDAR antagonist
approved in 2003 for the treatment of moderate-to-severe AD
and dementia. In clinical trials, memantine has shown significant
benefits on cognition, function, and global status of AD patients.
Moreover, it appears to be harmless and well-tolerated, with
a safety profile compared to placebo (Doody et al., 2007).
Memantine binds to NMDARs with a low-micromolar IC50
value. Furthermore, it exhibits poor selectivity among NMDARs
subtypes, with under micromolar IC50 values for NR2A,
NR2B, NR2C, and NR2D receptors expressed in Xenopus oocytes
(Parsons et al., 1999). Althoughmemantine was initially regarded
as a poor drug candidate for AD therapy, the mechanisms by
which exerts clinical benefits and its safe profile have attracted
a great considerable interest in the field of medicinal chemistry
(Lipton, 2006). In addition, memantine has also been reported to
exhibit neuroprotective activities against Aβ toxicity (Tremblay
et al., 2000; Miguel-Hidalgo et al., 2002; Hu et al., 2007), tau
phosphorylation (Song et al., 2008), neuroinflammation (Willard
et al., 2000), and oxidative stress (Figueiredo et al., 2013; Liu
et al., 2013).
FIGURE 4 | Chemical structures of FDA-approved agents for use in AD: tacrine (1), donepezil (2), rivastigmine (3), galantamine (4), and memantine (5).
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Donepezil
Donepezil, marketed under the trade name of Aricept R© in 1996,
is a brain-permeable reversible non-competitive ChE inhibitor
approved for use in AD (Birks and Harvey, 2006) and currently
the most widely prescribed drug for the treatment of this
disease. Donepezil is highly selective for AChE over BuChE
activity (405:1) (Nochi et al., 1995). Compared to other approved
AChE inhibitors, donepezil is similarly effective in ameliorating
cognitive and functional decline in AD with comparable safety
and tolerability. Moreover, beneficial effects have been observed
at lower doses (5mg/day), which is highly valuable at minimizing
adverse reactions. Although clinical trials with donepezil have
been reported, modest but reproducible, improvements in
cognition and global functioning in treated patients, as compared
to placebo. These effects were not permanent as patients,
continued to exhibit a decline in cognitive functioning over time
(Doody et al., 2007).
In recent years, the consistent failure of pharmacological
approaches targeting traditional AD targets such as Aβ and tau
protein together with the existing number of drugs to be tested in
pre-dementia stages of the disease has left no effective disease-
modifying treatment of AD in sight. Thus, additional benefits
of donepezil might be revealed with the use of this molecule in
combination with other active moieties.
MULTI-TARGET-DIRECTED LIGANDS
(MTDL)
The lack of therapeutic effectiveness of the current FDA-
approved drugs based on the single-target paradigm for
the treatment of cognition and memory decline, prompted
to the rational design and development of a novel and
improved pharmacological approach against AD: the Multi-
Target-Directed Ligands (MTDL) or “dirty drugs” (Buccafusco
and Terry, 2000; Youdim et al., 2005; León et al., 2013). These
molecules are conceived to directly interact weakly with multiple
targets associated with AD by the molecular hybridisation
of different pharmacophore moieties from identified bioactive
molecules. The development of MTDLs obviates the challenge
of simultaneously administering multiple drugs with potentially
different degrees of bioavailability, pharmacokinetics, and
metabolism. Furthermore, this pharmacological approach also
provides AD patients with a simplification of the therapeutic
regimen (Figure 5).
To date, the therapeutic potential of MTDLs for the treatment
of complex neurodegenerative diseases and age-related cognitive
impairment has not been realized. Multifaceted diseases such as
AD, mainly caused by perturbations of the complex intracellular
network that links to tissue and organs systems, needs a
more comprehensive pharmacological approach. Therefore,
approaches relying on targeting single proteins/mechanisms are
not likely to have effective outcomes. Because of the existence of
feedback mechanisms in biological systems, enzyme inhibition
may not be able to decrease activity in long term, but instead,
may result in increased activity, as reported from the use of
rapid-reversible AChE inhibitors that significantly increased both
protein activity and expression levels in the CSF of AD patients
after long-term treatment (Darreh-Shori and Soininen, 2010).
Since 2005, literature has shown several promising results
from applying this innovative approach to drug design. Well-
known drugs such as donepezil, tacrine, or rivastigmine
(Bolognesi et al., 2007; Samadi et al., 2011) as well as
bioactive natural products such as curcumin (Malar and Devi,
2014), berberine (Jiang et al., 2011; Shan et al., 2011), or
8-hydroxyquinoline (Gomes et al., 2014) have been used as
structural scaffolds for the development and search of new
chemical entities with multiple properties or MTDLs for the
treatment of AD. These new entities may be considered as
simplified versions or lead drugs possessing great potential as
real alternatives to the current unsuccessful pharmacological
therapies for effectively fighting against AD and other complex
diseases.
The next sections include an overview on the outcomes
obtained from the biological assessment of several MTDLs
molecules that have been lately reported by some of us. All
the compounds described bear the N-benzylpiperidine group
present in donepezil and the N-propargylamine motif present
in PF9601N, a potent and selective MAO B inhibitor with
neuroprotective effects in vitro and in vivo using different
experimental models of neurodegenerative diseases (Cutillas
et al., 2002; Pérez and Unzeta, 2003; Pérez et al., 2003; Battaglia
et al., 2006; Sanz et al., 2009). Both scaffolds were linked by
different heterocyclic ring systems, such as pyridine, indole or
8-hydroxyquinoline, allowing the facile synthesis of different
MTDL molecules as promising drugs to be used in AD therapy
(Figure 6). The inhibitory profile of these new MTDL molecules
inhibiting ChE and MAO, their antioxidant, anti-β-aggregating,
anti-inflammatory, and anti-apoptotic behavior together with
their metal-chelating properties were determined and results
from comparative studies were assessed. Taken together, the
outcomes reported with these derivatives reveal a potential
improvement of the current pharmacological therapy of AD.
ASS234
ASS234 {N-[5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-
1H-indol-2-ylmethyl]-N-methylprop-2-yn-1-amine} (Figure 7)
was first identified by some of us as a suitable candidate for use
in AD as a result of extensive screening of several series of novel
derivatives. This multipotent molecule was specifically developed
to combine the anti-cholinergic activity of donepezil, as an AChE
inhibitor widely used in AD therapy, with a propargylamine
moiety derived from selective MAO B inhibitor, PF9601N
(Figure 7) with neuroprotective properties (Bolea et al., 2011).
ASS234 was revealed as a potent inhibitor of both MAO
A and MAO B, with an IC50 values of 5.2 ± 1.1 nM and
43.1 ± 7.9 nM, respectively. It also inhibited both ChEs
exhibiting IC50 values of 0.35 ± 0.001 and 0.46 ± 0.06 µM
toward AChE and BuChE, respectively. In comparison with
donepezil and PF9601N, analyzed under the same experimental
conditions, donepezil was ineffective at inhibitingMAO activities
whereas PF9601N potently and selectively inhibited MAO B
isoform but displayed no interaction with both ChEs (Bolea
et al., 2011). These data indicate that ASS234 combines the
Frontiers in Neuroscience | www.frontiersin.org 11 May 2016 | Volume 10 | Article 205
Unzeta et al. New MTDLs for Alzheimer’s Disease
FIGURE 5 | Scheme of the therapeutic design strategy of MTDL for the treatment of the multifaceted nature of AD pathology.
FIGURE 6 | Structure of compounds PF9601N, ASS234, and the MTDL1-4 described in this review.
desirable properties of donepezil and PF9601N being capable of
simultaneously enhancing both cholinergic and monoaminergic
transmission as well as possessing neuroprotective effects (Bolea
et al., 2013a).
Kinetic studies showed that ASS234 is a-reversible inhibitor
of both ChEs, with micromolar affinity, and a highly potent
irreversible MAO A inhibitor with similar behavior to clorgyline
(Esteban et al., 2014). The parent propargylamine, PF9601N,
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FIGURE 7 | Design strategy of ASS234. IC50 values (in µM) of donepezil, PF9601N and ASS234 inhibiting both ChEs and MAO activities are shown Bolea et al.
(2011).
behaves similarly to l-deprenyl as an effective selective MAO B
inhibitor. Both PF9601N and ASS234 display as mechanism-
based MAO inhibitors. The selectivity of ASS234 as a MAO A
inhibitor, indicated by the IC50 values, for both purified and
membrane-bound protein samples (Pérez et al., 1999; Bolea
et al., 2011), might be attributed to the shared propargylamine
structure, which is larger and more hydrophobic in ASS234.
The initial reversible binding parameter (Ki value of 0.2 µM)
indicated thatASS234 has slightly lower affinity for MAOA than
clorgyline (Ki value of 0.04 µM), and this was also reflected in
higher rate constant (k1) for the irreversible reaction.
UV-VIS spectral analyses showed an irreversible modification
of the MAO flavin group by ASS234 similar to that found with
other propargyl MAO inhibitors. The crystal structure of human
MAO B in complex with ASS234 revealed the formation of a
covalent adduct with the N5 atom of the flavin cofactor. The N-
benzylpiperidine moiety of the compound was not able to fully
bind to the intact molecule to the MAO B active site, which
ruled out the possibility that the inhibitor may have undergone
degradation. Thus, these outcomes demonstrated the efficacy
of ASS234 as inhibitor of both the “classic” AD-targeted ChE
enzymes and the MAOs (Esteban et al., 2014).
Following the search for additional activities with multi-
target ASS234, the potential modulation of the monoaminergic
transmission and metabolism by this molecule were also
investigated both in vitro and in vivo (Van Schoors et al.,
unpublished results). Since some of the behavioral alterations
occurring in AD such as depression are possibly caused
by monoaminergic dysfunction, the therapeutic use of
antidepressant drugs based on the selective inhibition of
MAO A, an enzyme possessing an indispensable role in the
metabolic regulation of neurotransmitters 5-HT, NA, DA, and/or
on the blockage of the corresponding reuptake systems at the
pre-synaptic nerve endings, may also be considered.
In this context, a significant increase in the levels of 5-HT
associated with a reduction in the levels of its metabolite 5-HIAA
was observed as a result of irreversible inhibition of MAO A
in SH-SY5Y cells treated with ASS234. Comparatively, similar
though less pronounced effects were found with highly-selective
MAO A inhibitor clorgyline under the same experimental
conditions, thus revealing an active effect of this multi-target
drug to in enhancing 5-HT levels. In contrast, DA levels were
significantly decreased in PC12 cells that had been treated with
ASS234 for 24 h. This finding may be due to a reduction
of both activity and expression of the enzymes responsible
for DA synthesis, tyrosine hydroxylase and aromatic L-amino
acid decarboxylase as a response to initial rapid elevation of
DA levels following the blockage of MAO activity. Both MAO
A inhibitors ASS234 and clorgyline were able to modulate
the levels of DA metabolites DOPAC and HVA, which were
decreased after incubations. In vivo microdialysis studies of the
effects upon administration of ASS234 in freely-moving rats also
revealed alterations in the extracellular monoamines levels in
both hippocampus and prefrontal cortex, two brain areas that
are highly-impaired in AD. Interestingly, the effect of ASS234
differed from brain areas and dosage. In hippocampus, levels
of 5-HT and NA were increased whereas those of DA and NA
markedly augmented in prefrontal cortex.
These differences might be attributed to the presence of
metabolizing enzymes in both brain areas as well as to the
complexity of the monoaminergic neurochemical interactions
existing in the brain. In addition, ASS234, as a multi-target
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compound, might be able to modulate other neurobiological
systems and therefore producing a complex pharmacological
outcome. The results from the in vivo studies revealed a
time-dependent effect on extracellular levels of monoaminergic
neurotransmitters after administration of a single, subcutaneous,
dose of ASS234. This results could be used in further studies
to assess both the pharmacokinetics and bioavailability of the
compound in reaching its therapeutic target. Many factors,
including route of administration and the existence of active
metabolites may contribute to the observed delay in the in vivo
effects observed with ASS234.
In AD, levels of DA and NA are diminished in cortex and
hippocampus while those of 5-HT are decreased in hippocampus
(Reinikainen et al., 1988), producing some distinctive behavioral
symptoms including depressive-like disorder, psychosis, or
memory impairment related to alterations in serotonergic,
catecholaminergic, and cholinergic neurotransmissions
(Vermeiren et al., 2015). Therefore, the outcomes observed
in vivo upon the administration of ASS234 in addition with
those previously found, confirm the potential value of this
compound to be used as a modulator of the monoaminergic
transmission in AD, both in terms of therapy and for further
elucidation of the mechanisms involved.
The therapeutic potential of ASS234 has been also evaluated
following its administration to a rat model of vascular dementia
(Stasiak et al., 2014). These experiments involved the permanent
bilateral occlusion of the common carotid arteries (BCCAO)
with experimental vascular dementia. In this rat model, the
administration of ASS234 for five consecutive days resulted in
a potent and selective inhibition of brain MAO A activity as well
as a concurrent increase in the concentrations of serotonin and
catecholamines dopamine and noradrenaline. BCCAO resulted
in impaired time parameters and memory functions as measured
by hole-board memory tests in rats. Treatment of BCCAO rats
withASS234 showed less negative effects on cognitive parameters
and exerted a significant positive effect on working memory.
Aggregation and deposition of Aβ is a key pathological
hallmark of AD and there is increasing evidence suggesting that
the neurotoxicity of this peptide is related to the formation
of toxic oligomeric aggregates. In this regard, ASS234 has
demonstrated to possess anti-Aβ1−42 aggregating capacity and
also an ability to reduce the presence of oligomeric forms
of β-amyloid, as the most toxic species in AD (Bolea et al.,
2013a). Moreover, ASS234 was able to inhibit AChE-catalyzed
Aβ aggregation by binding to the PAS of the enzyme.ASS234 also
showed a protective effects on the Aβ1−42-mediated cytotoxicity
induced in human neuroblastoma cells by preventing the
activation of the intrinsic mitochondrial pathway of apoptosis.
Moreover, ASS234 displayed significant antioxidant properties,
arising from the increase in the expression of catalase and SOD-
1 in human neuroblastoma SH-SY5Y cells. This compound also
has the capacity to capture free radicals in vitro, as measured
by the well-established ORAC-FL (Oxygen radical Absorbance
Capacity) fluorescent method. It is noteworthy that in a recent
in vivo approach using transgenic APP/PS1AE9 mice given
ASS234, both Aβ plaques in cortex and activated glia were found
decreased (Serrano et al., 2016).
These findings, summarized in Figure 8, allow us to conclude
that ASS234 is able to interact with multiple targets relevant
to AD. They also indicate that this is an interesting MTDL
molecule that should be considered for therapeutic development
against AD.
Derivatives MTDL-1 and MTDL-2
(Donepezil-Pyridyl and Indolyl-Propargyl
Hybrids) as Dual ChE/MAO Inhibitors
With the aim of searching for improved MTDLs, two series
of novel structurally-derived compounds, derived from ASS234
as multipotent donepezil-indolyl and donepezil-pyridyl hybrids
were designed and pharmacologically evaluated for their
potential use in AD. The synthetic strategy that was used
to design these novel donepezil-pyridyl hybrids is outlined in
Figures 9, 10.
Among all the compounds tested, the donepezil-pyridyl
hybrid MTDL-1 (Figure 9) was identified as a potent AChE
inhibitor (IC50 = 1.1 nM) and a moderate BuChE inhibitor
(IC50 = 0.6 µM) with total selectivity toward human MAO B
(Bautista-Aguilera et al., 2014a). Interestingly, the design and
development of non-selective ChE inhibitors for use in AD
appears of valuable pharmacological concern, as the hydrolysis
of neurotransmitter ACh may largely occur via BuChE catalysis
in aged AD brains, the activity levels of which have been found
elevated on late-stages of the disease as it is also the case with
MAO B. Since BuChE is also found in glial cells that are recruited
and activated around the plaques and tangles, the inhibition
of this enzyme might provide additional benefits at reducing
neuroinflammation. Suitable drug-likeness profile and ADMET
properties of these two novel MTDLs were also confirmed by
3D-QSAR studies.
The donepezil-indolyl hybrid moleculeMTDL-2 (Figure 10),
exhibited an interesting profile as potent MAO A inhibitor
(IC50 = 5.5 nM) that was moderately able to inhibit MAO
B (IC50 = 150 nM), AChE (IC50 = 190 nM), and BuChE
(IC50 = 830 nM) (Bautista-Aguilera et al., 2014b). Moreover,
this compound appeared to be a mixed-type AChE inhibitor
able to span both the CAS and PAS of this enzyme, as
found by molecular modeling studies. Interestingly, docking
simulations revealed that the selective inhibition of MAO
isoforms by propargyl-containing compounds accounts for the
orientation on their propargylamine and phenyl moieties in
MAO, which energetically affects the interaction with the active
site.
Derivatives MTDL-3 and MTDL-4
(Donepezil+Propargylamine+8-
Hydroxyquinoline Hybrids) As Dual
ChE/MAO Inhibitors with Antioxidant
Activity, Metal-Chelating Properties, and
Other Pharmacological Targets
Newly-designed MTDL-3 and MTDL-4 derivatives containing
the N-benzylpiperidine moiety from donepezil and a metal-
chelating 8-hydroxyquinoline group (Figures 11, 12), were
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FIGURE 8 | Schematic representation of ASS234 targets involved in AD pathogenesis. ASS234 forms a N5 flavin adduct (like clorgyline) with MAO A and it is
able to block AChE-induced Aβ aggregation. ASS234 shows antioxidant and anti-apoptotic properties and it is able to induce neuroprotection through the Wnt
pathway. ASS234 also shows less toxicity than donepezil in HepG2 cells (With permission of Bolea et al., 2013b).
linked to a centralN-propargylamine core and pharmacologically
evaluated (Wang et al., 2014; Wu et al., 2015). This molecule
contains a moiety also present in the compound M30, a
brain-permeable and iron-chelating compound with antioxidant
activity displaying neuroprotective activity in animal models
(Salkovic-Petrisic et al., 2015). M30 modulates HIF-α-related
glycolytic genes in the frontal cortex of APP/PS1 mice used
as AD model (Mechlovich et al., 2014). These studies also
showed M30 to have beneficial effects on several major
hallmarks of AD (Kupershmidt et al., 2012), indicating the
potential value of incorporating this moiety into MTDL-3
(Figure 11).
MTDL-3 was revealed as an irreversible MAO inhibitor and
mixed-type ChE inhibitor, in low micromolar range, able to
strongly complex Cu (II), Zn (II), and Fe (III) (Wang et al., 2014).
In addition, the cyano group, which was only present in some
derivatives, was found to enhance the binding to AChE, BuChE,
and MAO A (Wang et al., 2014). Although α-aminonitriles
have seldom been investigated as ChE inhibitors, some previous
studies described nitriles as MAO inhibitors, and reported that
cyanide potentiates irreversible MAO inhibition (Ramadan et al.,
2007). Although cyanide is known to be a poor reversible
inhibitor of the oxidation of benzylamine by MAO (Houslay and
Tipton, 1973), previous studies have indicated that the inhibitory
activity of several compounds against MAO is potentiated by
cyanide (Davison, 1957; Ramadan and Tipton, 1998; Ramadan
et al., 1999, 2007; Juárez-Jiménez et al., 2014). An earlier study
by Davison (1957) on the inhibition of mitochondrial MAO by
the irreversible inhibitor iproniazid revealed that, although at low
concentrations, this compound alone had little effect on enzyme
activity, while the inhibitory activity was significantly enhanced
in the presence of cyanide ions. A similar potentiating effect was
also reported for phenelzine and pheniprazine (Ramadan et al.,
1999). Such studies demonstrated that, in case of pheniprazine,
cyanide potentiates the inhibition by increasing the apparent
binding affinity to MAO without producing significant changes
in the rate of the reaction that yields the irreversibly inhibited
species (Ramadan et al., 2007). This finding suggests that the
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FIGURE 9 | Designed structure of hybrid MTDL1 and IC50 values for the
inhibition of ChE and MAO enzymes (Bautista-Aguilera et al., 2014a).
FIGURE 10 | Structure of hybrid MTDL2 and IC50 values for the
inhibition of ChEs and MAO enzymes (Bautista-Aguilera et al., 2014b).
potentiating effect of cyanide can be ascribed to an activation
mechanism whereby cyanide assists the binding of the inhibitor
to the enzyme.
Theoretical ADMET analyses, showed MTDL-3 to
exhibit good drug-likeness properties and brain penetration
capacity for CNS activity. Moreover, less toxicity than
donepezil in HepG2 cells was also revealed with these
derivatives. These findings are important, of noteworthy
FIGURE 11 | Structure of hybrid MTDL3 and IC50 values for the
inhibition of ChEs and MAO enzymes (Wang et al., 2014).
relevance since the simultaneous administration of multiple
therapeutic agents (polypharmacology) may lead to potentially
lethal side effects triggered by drug-to-drug interactions.
Therefore, such undesirable outcomes might be significantly
reduced by the use of multi-target derivatives such as
MTDL-3. Furthermore, these molecules also displayed
good performance in terms of translational science since
scopolamine-induced memory deficits were partially restored
by MTDL-3, confirming its effective pharmacokinetics
in vivo.
Another related molecule, MTDL-4 (Figure 12),
showed similar behavior as dual ChE/MAO inhibitor
(Wu et al., 2015), which was identified from an initial
pharmacological screening as an appropriate lead compound
for further investigation. Subsequent investigations
revealed further potentially valuable properties of this
molecule.
CONCLUDING REMARKS
Overall, the findings presented in this review robustly reinforce
the suitability of MTDLs as an appropriate pharmacological
approach to target disease progression in AD therapy.
Amongst all the compounds tested, multi-target MTDL-3
particularly emerged as a ligand possessing a number of
remarkable potential benefits for use in this neurological
disorder including well-balanced dual AChE/MAO inhibition,
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FIGURE 12 | Structure of hybrid MTDL-4 and IC50 values for the inhibition of ChEs and MAO enzymes (Wu et al., 2015).
strong metal-chelating activity, neuroprotective and anti-
apoptotic properties, potent antioxidant capacities and
anti-inflammatory action. Furthermore, MTDL-3 has effects as
enhancer of cognitive functions. This prompts us to propose
this molecule as the first racemic α-aminonitrile identified
so far as a multifunctional chelator for biometals able to
interact in two key enzymatic systems implicated in AD.
We consider it as an important new lead compound that
merits further investigation for the potential treatment of this
disease.
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